

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Elazar Rabbani et al.
 Serial No. 08/978,634 Group Art Unit: 1635
 Filed: November 25, 1997 Examiner: Mary M. Schmidt



Title: MULTIMERIC COMPLEX COMPOSITIONS AND DELIVERY
 PROCESSES USING SAME (As Previously Amended)

FILED BY FIRST CLASS MAIL

Honorable Commissioner of
 Patents and Trademarks
 Washington, D. C. 20231

RECEIVED
 AUG 25 1999
 TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment Under 37 C.F.R. § 1.115 (In Response
 To The February 17, 1999 Office Action) in the above-identified patent application.

The fee* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	58	Minus	35	0=	X\$9.00	\$ 0
Indep	3	Minus	3	0=	X\$39.00	\$ 0
()	First Presentation of Multiple Dependent Claims				\$130.00	\$
	TOTAL ADDITIONAL FEE					\$ 0

*Small entity status was previously established in this application and is still applicable.

- () Charge Deposit Account No. 05-1135 in the amount of \$ _____
- () A check in the amount of \$ _____ is attached.
- (X) The Commissioner is hereby authorized to charge payment of the following
 fees associated with this communication or credit any overpayment to Deposit
 Account No. 05-1135 any filing fees under 37 C.F.R. §1.16 for the presentation of
 extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.


Also enclosed: Request For An Extension Of Time (Three Months); Second
 Amendment In Connection with Notice To Comply With Requirements For Patent
 Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence
 Disclosures Under 37 CFR §§1.821-1.825; Communication Directed To Notice To
 Comply With Sequence Rules; Initial Paper Copy of the Sequence Listing; Computer
 Readable Form copy of the Sequence Listing; Declaration Under 37 CFR §1.821(g)

Respectfully submitted,

Ronald C. Fedus
 Registration No. 32,567
 Attorney for Applicants

August 17, 1999
 Date

ENZO THERAPEUTICS, INC.
 c/o Enzo Biochem, Inc.
 527 Madison Avenue (9th Fl.)
 New York, New York 10022
 Tel. (212) 583-0100
 Attorney's Docket No.: Enz-53(D2)
 lclTransmittalAmendment.ENZ53.D4.081699



BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al.

Serial No. 08/978,634

Filed: November 25, 1997

Title: MULTIMERIC COMPLEX COMPOSITIONS
AND DELIVERY PROCESSES USING
SAME (As Amended)



Group Art Unit: 1635

Examiner: Mary M. Schmidt

527 Madison Avenue, 9th Floor
New York, New York 10022
August 17, 1999

FILED BY FIRST CLASS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Attention: Box Sequence


**COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**

Dear Sirs:

This Communication is directed to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures referenced in the Office Action issued February 17, 1999 which issued in connection with the instant application. While a copy of the Notice was not attached to Applicants' copy of the aforementioned Office Action, Applicants hereby submit the following documents or items:

1. a substitute paper copy of the Sequence Listing;
2. a Second Amendment directing entry of the Sequence Listing into the specification;
3. a computer readable form (CFR) copy of the substitute Sequence Listing; and

ENZ-53(D2)




BEST AVAILABLE COPY

4. a Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper copy and computer readable copy are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of Time (Three Months Under 37 C.F.R. .§1.136(a). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl.)
New York, New York 10022
(212) 583-0100

LC/USProsecution/Enz53(D2)/communication.re.sequence.rules081799.enz53(D2)

BEST AVAILABLE COPY

ENZ-53(D2)